Chronic Kidney Disease

Results From the STEP Trial in China

Unmet Needs in the Management of Heart Failure

Results From the EMPEROR-Pooled Analysis

Results From EMPEROR-Preserved: CV Outcomes in Patients With HFpEF

Results From FIGARO-DKD and FIDELITY: Finerenone + SGLT2 Inhibitors

Practical Implications of the FIDELITY Pooled Analysis

Results From the FIDELITY Pooled Analysis

An Overview of the FIDELITY Pooled Analysis Design

Results From FIGARO-DKD: Finerenone’s Impact on Type 2 Diabetes and CKD

An Overview of the FIGARO-DKD Trial Design

Recognizing and Addressing Primary Aldosteronism in Hypertension Management: Vivek Bhalla, MD

Ensuring Access to Pegcetacoplan Requires Updated Guidelines, Education, and Distribution Solutions: Carla Nester, MD, MSA, FASN

Iptacopan Outshines Past C3G Treatments: Carla Nester, MD, MSA, FASN

Atrasentan Has Promising Long-Term Potential in IgA Nephropathy: Richard Lafayette, MD, FACP

New Hope for IgA Nephropathy With Atrasentan Approval: Richard Lafayette, MD, FACP

UPMC's Dr Manisha Jhamb Urges Better Kidney Disease Awareness, Integrated Care

Current Status of Chronic Kidney Disease in the US

Navigating CKD Treatment Among Comorbidities

Dr Kirsten Johansen on Benefits of Oral Therapies for the Management of CKD

Empagliflozin Has Similar Efficacy Across Subgroups, More Data Needed in CKD: Dr Jennifer Green

Engage, Educate, Empower: Transforming Kidney Care

More Needs to Be Done to Reduce Racial Disparities in Home Dialysis

Advocating for All Patients With Chronic Kidney Disease

Managing Disparities in Chronic Kidney Disease Through Value-Based Arrangements

Examining the Shift to Value-Based Kidney Care Delivery in 2021